Tiziana Life Sciences, Ltd. (TLSA) Doses First ALS Patients in Phase 2a Trial
Tiziana Life Sciences dosed the first three participants with intranasal foralumab in the Phase 2a Healey ALS MyMatch BANYAN trial, evaluating biomarker effects and safety in ALS.Material DetailsContext by AI AnalystThis is an early clinical execution milestone for Tiziana’s lead program expanding…